Alterity Therapeutics Limited (ASX:ATH)
Australia · Delayed Price · Currency is AUD 0.4600
-0.0200 (-4.17%)
Sep 11, 2026, 11:20 AM AEST
Alterity Therapeutics Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Other Revenue | 3.61 | 5.44 | 4.02 | 3.92 | 5.12 |
| 3.61 | 5.44 | 4.02 | 3.92 | 5.12 | |
Revenue Growth | -33.63% | 35.32% | 2.63% | -23.56% | 18.06% |
Cost of Revenue | 0.26 | 0.13 | 0.21 | 0.29 | 0.36 |
Gross Profit | 3.35 | 5.31 | 3.8 | 3.63 | 4.76 |
Selling, General & Admin | 10.53 | 5.48 | 4.76 | 5.06 | 5.51 |
Research & Development | 17.63 | 14.4 | 18.64 | 13.2 | 14.75 |
Other Operating Expenses | 0.28 | 0.09 | 0.01 | 0.03 | 0 |
Operating Expenses | 28.44 | 19.97 | 23.41 | 18.27 | 20.26 |
Operating Income | -25.09 | -14.66 | -19.61 | -14.64 | -15.5 |
Interest & Investment Income | 1.72 | 0.45 | 0.27 | 0.02 | 0 |
Currency Exchange Gain (Loss) | 0.09 | 0.26 | 0.26 | 0.92 | 2.72 |
Other Non Operating Income (Expenses) | - | -0.33 | - | - | - |
EBT Excluding Unusual Items | -23.29 | -14.28 | -19.08 | -13.7 | -12.78 |
Other Unusual Items | - | 1.98 | - | - | - |
Pretax Income | -23.29 | -12.08 | -19.08 | -13.7 | -12.78 |
Income Tax Expense | 0.11 | 0.07 | 0.05 | 0.1 | 0.07 |
Net Income | -23.4 | -12.15 | -19.12 | -13.81 | -12.85 |
Net Income to Common | -23.4 | -12.15 | -19.12 | -13.81 | -12.85 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 210 | 128 | 73 | 49 | 48 |
Shares Outstanding (Diluted) | 210 | 128 | 73 | 49 | 48 |
Shares Change | 64.53% | 75.31% | 50.29% | 0.91% | 41.79% |
EPS (Basic) | -0.11 | -0.09 | -0.26 | -0.28 | -0.27 |
EPS (Diluted) | -0.11 | -0.09 | -0.26 | -0.28 | -0.27 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Free Cash Flow | -22.52 | -11.45 | -12.61 | -20.04 | -12.43 |
Free Cash Flow Per Share | -0.11 | -0.09 | -0.17 | -0.41 | -0.26 |
Gross Margin | 92.72% | 97.66% | 94.67% | 92.72% | 92.88% |
Operating Margin | -695.13% | -269.57% | -487.82% | -373.72% | -302.56% |
Profit Margin | -648.22% | -223.35% | -475.79% | -352.54% | -250.75% |
Free Cash Flow Margin | -623.91% | -210.54% | -313.78% | -511.78% | -242.54% |
EBITDA | -25.09 | -14.63 | -19.57 | -14.6 | -15.48 |
EBITDA Margin | - | -269.05% | - | - | - |
D&A For EBITDA | 0 | 0.03 | 0.04 | 0.04 | 0.02 |
EBIT | -25.09 | -14.66 | -19.61 | -14.64 | -15.5 |
EBIT Margin | - | -269.57% | - | - | - |